Tag: biomarker

Medidata and the University of Sydney’s NHMRC Clinical Trials Centre Broaden Efforts to Revolutionize Clinical Studies in Australia

Continuing collaboration will utilize the capabilities of the Medidata Data Experience, fostering efficiency, fast-tracking research breakthroughs, and raising the standard of clinical trials SINGAPORE,...

Medidata and the University of Sydney’s NHMRC Clinical Trials Centre Broaden Efforts to Revolutionize Clinical Studies in Australia

Continuing collaboration will utilize the capabilities of the Medidata Data Experience, fostering efficiency, fast-tracking research breakthroughs, and raising the standard of clinical trials SINGAPORE,...

Mercy BioAnalytics Appoints Dr. Prasanth Reddy as Chief Medical Officer

WALTHAM, Mass., July 8, 2025 /PRNewswire/ -- Mercy BioAnalytics, Inc., a pioneer in extracellular vesicle-based liquid biopsies for the early detection of cancer, today...

Lifeforce and Toku Combine AI Retinal Scans with the World’s Largest Longevity-Medicine Platform to Take Steps to Slow Aging and Reduce Cardiovascular Risk

SANTA MONICA, Calif., July 7, 2025 /PRNewswire/ -- Lifeforce, the world's largest longevity medicine platform, and Toku, a health technology company using AI to...

mRNA Sequencing Market Size to Hit USD 4.02 billion by 2031, Growing at 13.6% CAGR, Benefits from Surging Prevalence of Cancer | The Insight...

NEW YORK, July 7, 2025 /PRNewswire/ -- According to a new comprehensive report from The Insight Partners, the global mRNA sequencing market is observing...

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

PRESS RELEASE

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation...

Promising monotherapy activity observed in all three major metastatic colorectal cancer subtypes harboring high tumor mutational burden (MSS RASwt, MSS RASmut and PD-1 resistant MSI-H)...

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Recruitment initiated into the Phase 2 opaganib plus darolutamide study in patients with advanced prostate cancer, sponsored by ANZUP, and supported by Bayer and...

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

– Conditional approval based on positive results from the HERIZON-BTC-01 Phase 2b trial – DUBLIN, July 1, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ)...

Rapid Diagnostics Market to Reach $24.28 Billion by 2032, Growing at a CAGR of 6.6% from 2025, Says Meticulous Research®

Market Growth Driven by Rising Demand for Point-of-Care Diagnostics, Increasing Prevalence of Chronic and Infectious Diseases, Emergency Department Needs, and Technological Innovations REDDING, Calif., June...

Epigenica Closes $2.2 Million Investment Round to Scale Cutting-Edge Epigenetic Solutions

Financing to accelerate commercialization of flagship products, service business, and entrance into U.S. market STOCKHOLM, June 30, 2025 /PRNewswire/ -- Epigenica AB, a pioneer in high-throughput...

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA^®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months.

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

The anti-CCR8 antibodies market holds potential in addressing unmet needs across inflammatory and cancerous diseases. The anti-CCR8 inhibitor market is expected to witness substantial...

SeAH Aerospace & Defense Receives Boeing’s Supplier Production Partner Award for Excellence in Aerospace Materials

Insta360 Launches Luna Ultra: Leica Co-Engineered Gimbal Camera Built for Next-Generation Mobile Filmmaking

ToolGen Opens Advanced Field Testing Facility in Osong, Completing ‘Bench-to-Field’ Commercialization Platform for Global SAF and Industrial Crop Markets

Medidata and the University of Sydney’s NHMRC Clinical Trials Centre Broaden Efforts to Revolutionize Clinical Studies in Australia

Medidata and the University of Sydney’s NHMRC Clinical Trials Centre Broaden Efforts to Revolutionize Clinical Studies in Australia

Mercy BioAnalytics Appoints Dr. Prasanth Reddy as Chief Medical Officer

Lifeforce and Toku Combine AI Retinal Scans with the World’s Largest Longevity-Medicine Platform to Take Steps to Slow Aging and Reduce Cardiovascular Risk

mRNA Sequencing Market Size to Hit USD 4.02 billion by 2031, Growing at 13.6% CAGR, Benefits from Surging Prevalence of Cancer | The Insight...

AB Science: Masitinib receives FDA and EMA authorization for confirmatory phase 3 trial in metastatic castrate-resistant prostate cancer

Marengo Presents Monotherapy Activity of Invikafusp Alfa, a First-in-Class Selective Dual T Cell Agonist in PD-1 Resistant GI Tumors, as a Late-Breaking Oral Presentation...

RedHill Biopharma Announces Recruitment Initiated into Expanded Phase 2 Opaganib/Darolutamide Combination Study in Advanced Prostate Cancer

Jazz Pharmaceuticals Receives European Commission Marketing Authorization for Ziihera® (zanidatamab) for the Treatment of Advanced HER2-Positive Biliary Tract Cancer

Rapid Diagnostics Market to Reach $24.28 Billion by 2032, Growing at a CAGR of 6.6% from 2025, Says Meticulous Research®

Epigenica Closes $2.2 Million Investment Round to Scale Cutting-Edge Epigenetic Solutions

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

Anti-CCR8 Antibodies Market to Witness Remarkable Growth Trajectory During the Forecast Period (2025-2040) Across 7MM | DelveInsight

Explore

Press Releases

News & Opinion

Living

Others

Follow us